NasdaqGS:AKROBiotechs
A Fresh Look at Akero Therapeutics (AKRO) Valuation Following Positive Phase 2b HARMONY Trial Results
Akero Therapeutics (AKRO) just revealed the final 96-week results from its Phase 2b HARMONY trial for efruxifermin, an investigational therapy for people living with MASH and significant liver fibrosis. The data, published in The Lancet, showed sustained improvements in fibrosis and markers of metabolic health. This is a meaningful milestone for patients and investors alike. Given the complexity of MASH and the unmet need for new treatments, this clinical update is likely to influence how the...